CDC Clarifies Opioid Prescribing Guideline

Apr 9th, 2019 - ATLANTA -- Clinicians who prescribe opioids to control chronic pain in cancer patients, palliative care, and end-of-life care should follow recommendations of clinical practice guidelines specific to the settings, according to the CDC. Pain management in cancer, palliative care, and end-of-life care involves "unique therapeutic goals and balance of risks and benefits with opioid therapy," Debor...

CDC Clarifies: Okay to Prescribe Opioids for Cancer Pain

Apr 8th, 2019 - The Centers for Disease Control and Prevention (CDC) has issued a clarification letter that states the agency does not want to deny clinically appropriate opioid therapy to cancer and sickle cell disease patients, particularly those who are undergoing cancer treatment and survivors with chronic pain. The unusual issuance was addressed to three major cancer organizations who met with the CDC las...

CDC Clarifies: Okay to Prescribe Opioids for Cancer Pain

Apr 8th, 2019 - The Centers for Disease Control and Prevention (CDC) has issued a clarification letter that states the agency does not want to deny clinically appropriate opioid therapy to cancer and sickle cell disease patients, particularly those who are undergoing cancer treatment and survivors with chronic pain. The unusual issuance was addressed to three major cancer organizations who met with the CDC las...

CDC Issues Clarification on Guideline for Prescribing Opioids for Chronic Pain in Patients With Cancer and Sickle Cell Disease

Apr 8th, 2019 - ASCO, the American Society of Hematology (ASH), and the National Comprehensive Cancer Network® (NCCN®) are pleased to acknowledge receipt of a key clarification from the Centers for Disease Control and Prevention (CDC) on prescribing opioids to manage pain from certain conditions. The clarification regarding CDC’s Guideline for Prescribing Opioids for Chronic Pain—issued in a letter from the ag...

Less-Intensive Therapy Impresses in AML

Apr 5th, 2019 - More than half of older patients with untreated acute myeloid leukemia (AML) had rapid attainment of complete remission with the combination of venetoclax (Venclexta) and low-dose cytarabine, data from a single-arm clinical trial showed. The regimen led to complete remission with or without blood-count recovery in 44 of 82 patients, with a median time to first response of 1.4 months. The cohort...

Ig Overused in Immune Thrombocytopenia, Flash Mob Audit Shows

Apr 1st, 2019 - GLASGOW — Immune thrombocytopenia (ITP) patients in the UK are not being given intravenous immunoglobulin (IVIg) in line with current recommendations, potentially exposing them to risks, showed researchers in a novel form of audit presented at the British Society for Haematology (BSH) Annual Scientific Meeting. Immune thrombocytopenia patients in the UK have traditionally been given IVIg either...

Remembering Francesco Lo Coco, NYU Langone Health to Establish Center for Blood Cancers, and more

Apr 1st, 2019 - Remembering Francesco Lo Coco (1955 – 2019)  Francesco Lo Coco, MD, a renowned leukemia researcher and pioneer of targeted therapy, passed away on March 3, 2019. Members of the hematology community expressed shock and intense grief over this sudden loss. Dr. Lo Coco was born in Palermo, Italy. After earning his medical degree from the University of Pisa and completing his hematology training at...

ASH Expands Global Initiative, Awards Research Award to Minority Scholar

Apr 1st, 2019 - ASH Expands Global Initiative With Research Award for Hematologists Outside North America  The American Society of Hematology (ASH) Global Research Award was established in 2018 as part of the Society’s expanding global initiative to support the study of hematology and improve the quality of care outside of North America. The first eight winners, representing seven countries, were honored for t...

Impact of Benign Hematology Didactic Lectures on In-service Exam in a Hematology-Oncolo...
Journal of Cancer Education : the Official Journal of the American Association for Cancer Education; Lim MY, Greenberg CS

Mar 28th, 2019 - It remains unclear on whether the traditional formal didactic lecture sessions improve knowledge acquisition with conflicting data in the literature. This study evaluates the impact of an additional benign hematology didactic curriculum on the American Society of Hematology In-Service Exam (ASHISE). During the first 5 years of the study (2012-2016), formal didactic lectures consisted of medical...

ASH Reports Show Benefit of Adding Daratumumab to Initial Therapy in Multiple Myeloma

Mar 24th, 2019 - Kenneth Shain, MD, PhD DARATUMUMAB APPEARS to be the “gift that keeps on giving” to the myeloma community. “It seems we can add daratumumab to almost anything and make the regimen better. It’s got good activity and a good safety profile,” said Kenneth Shain, MD, PhD, Director of the Myeloma Working Group at Moffitt Cancer Center, Tampa, who commented on the benefit observed by adding the monocl...

Maintenance Ixazomib Delays Disease Progression in Newly Diagnosed Myeloma

Mar 24th, 2019 - IN PATIENTS with newly diagnosed multiple myeloma who responded well to induction therapy and underwent transplant, 2 years of maintenance therapy with ixazomib led to a 38% improvement in progression-free survival compared with placebo, according to the results of the phase III TOURMALINE-MM3 trial, presented at the 2018 American Society of Hematology (ASH) Annual Meeting & Exposition.1 Meleti...

Proposed 2020 Budget Would Slash Cancer Funding

Mar 22nd, 2019 - On March 11, President Donald Trump released his proposed fiscal year 2020 budget, which included a 12-percent cut to the U.S. Department of Health and Human Services (HHS) funding. That entails a $4.7 billion decrease in funding for the National Institutes of Health (NIH) – the U.S.’s largest provider of funding for biomedical research. The administration’s “A Budget for a Better America” also...

Update on Newer Treatments in Non-Hodgkin Lymphomas

Mar 9th, 2019 - Syed Ali Abutalib, MD Matthew Lunning, DO AS PART of The ASCO Post’s continued coverage of the 2018 American Society of Hematology (ASH) Annual Meeting & Exposition, here is an update on several different studies on new therapeutics in non-Hodgkin lymphomas (NHLs), including follicular lymphoma, diffuse large B-cell lymphoma (DLBCL), primary mediastinal B-cell lymphoma, and CD30-positive periph...

Roy L. Silverstein, MD, Begins Term as 2019 ASH President

Mar 9th, 2019 - ROY L. SILVERSTEIN, MD, an expert in platelet and vascular cell biology, as well as clinical nonmalignant hematology and thrombosis, will serve as President of the American Society of Hematology (ASH) for a 1-year term through December 2019. Roy L. Silverstein, MD Dr. Silverstein is Chairman of the Department of Medicine at the Medical College of Wisconsin (MCW) in Milwaukee, where he also serv...

ASH President Roy Silverstein, MD, Issues Comment on Maintenance of Certification Recommendations Draft

Mar 9th, 2019 - RECENTLY, THE American Society of Hematology (ASH) submitted feedback on draft recommendations for reforming Maintenance of Certification (MOC) to a commission appointed by the American Board of Medical Specialties (ABMS) and other entities. The “Vision Commission” released a report of its draft recommendations for reforming continuing board certification in December. ASH submitted comments on ...

Advances in Haploidentical Transplantation and Cellular Therapies

Mar 9th, 2019 - With advances in the field, the number of haploidentical stem cell transplants being performed (ie, using human leukocyte antigen [HLA] half-matched donor stem cells) has been increasing. In recognition of evolving strategies to improve outcomes, a group of transplant physicians started the Haploidentical Transplant Symposium (HAPLO) in 2012. Physicians and researchers continue to meet annually...

Priority review granted to lenalidomide for FL, MZL
Jennifer Smith

Mar 2nd, 2019 - The Food and Drug Administration has granted priority review to a supplemental new drug application (sNDA) for lenalidomide (Revlimid). Celgene is seeking approval for lenalidomide in combination with rituximab to treat patients with previously treated follicular lymphoma (FL) or marginal zone lymphoma (MZL).

Congress Passes Bipartisan Sickle Cell Bill

Mar 1st, 2019 - The U.S. Congress recently passed the Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2018, bipartisan legislation designed to improve the lives of patients living with sickle cell disease (SCD). The act includes provisions for the following: authorizing public health initiatives in SCD authorizing a SCD surveillance and data coll...

Avatrombopag for the treatment of immune thrombocytopenia.
Expert Review of Clinical Immunology; Długosz-Danecka M, Zdziarska J et. al.

Feb 25th, 2019 - Thrombopoietin-receptor agonists (TPO-RAs) are the only American Society of Hematology (ASH) guideline-advocated, second-line treatment for immune thrombocytopenia (ITP) that have been validated by randomized, controlled trials with a placebo comparator. Avatrombopag is a new candidate in this class that has been investigated as a treatment option for the treatment of ITP. Areas covered: In thi...

Midostaurin maintenance may reduce relapse risk in FLT3-ITD+ AML

Feb 25th, 2019 - Studies are increasingly suggesting that posttransplant maintenance therapy may improve this outcome. For example, the small, randomized, phase 2 SORMAIN study presented at the 2018 annual meeting of the American Society of Hematology showed a signal for benefit with posttransplant maintenance with the TKI sorafenib.